BioNTech SE - ADR vs Rent the Runway Inc — how do they compare? BioNTech SE - ADR trades at $90.88 (market cap $22.86B), while Rent the Runway Inc trades at $3.38 (market cap $109.66M). The key difference: BioNTech SE - ADR is far larger — about 208.5× Rent the Runway Inc's market cap, and BioNTech SE - ADR is trading nearer its 52-week high, Rent the Runway Inc nearer its low. Which is the better fit depends on your goals.
| BNTX | RENT | |
|---|---|---|
Market Cap | $22.86B | $109.66M |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $9.39 |
52-Week Low | $83.89 | $3.10 |
Enterprise Value | $6.53B | $269.76M |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
RENT trades at $3.34, down 0.3% on the day, with a bearish technical signal from moving averages. The company reported Q1 2026 revenue of $89.9 million, up 29.2% year-over-year, but continues to post net losses. Valuation ratios appear attractive with a P/E of 0.44 and P/S of 0.18, though negative equity of -$182.5 million raises concerns. Leadership transition is underway with the CEO stepping down in May 2026.
The outlook remains challenging despite revenue growth, as profitability and cash flow are negative. Analyst consensus is mixed with 42% buy ratings but significant debt and negative equity pose substantial risks. The stock offers potential upside if new initiatives improve margins, but execution risk is high amid leadership changes.
Trailing returns across standard periods
Latest headlines on both assets
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →